Influenza A virus H1N1 antigens (Hemagglutinin, Neuraminidase, Matrix protein 2) (H1N1 antigens)

Influenza A virus H1N1 antigens, primarily Hemagglutinin (HA) and Neuraminidase (NA), are the principal targets for the host immune response and pharmacological intervention. Hemagglutinin is a surface glycoprotein responsible for binding the virus to sialic acid receptors on host cells and facilitating membrane fusion for viral entry (Source: UniProt P03452). Neuraminidase is an enzyme that cleaves sialic acid to allow the release of newly formed viral particles from the host cell surface (Source: UniProt P03468). These proteins are the primary components of seasonal and pandemic influenza vaccines, designed to elicit neutralizing antibodies that block infection (Source: WHO, "Influenza (Seasonal)"). Additionally, NA serves as the target for neuraminidase inhibitors like oseltamivir, which limit viral spread within the host (Source: CDC, "Influenza Antiviral Medications"). The high rate of mutation in these antigens, known as antigenic drift, necessitates frequent vaccine updates and poses a constant challenge for long-term therapeutic efficacy (Source: PubMed PMC3074182). Understanding these targets is crucial for managing both seasonal outbreaks and potential pandemic threats associated with H1N1 strains.

Other names

H1N1 surface proteinsInfluenza A subtype H1N1 viral proteinsHemagglutinin and Neuraminidase (H1N1)Swine flu antigens

Inhibition of viral neuraminidase to prevent viral release; inhibition of M2 ion channel to prevent uncoating; induction of neutralizing antibodies against hemagglutinin to prevent viral entry.